Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Bimatoprost

02 1Cloprostenol Sodium

03 1Epoprostenol Sodium

04 1Latanoprost

05 1Latanoprostene Bunod

06 1Tafluprost

07 1Travoprost

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

01

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

02

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

03

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

04

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

05

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

06

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman

07

arrow
euroPLX 86 Munich
Not Confirmed

Cayman Pharma s.r.o

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry...

Cayman
Contact Cayman Pharma S.r.o and get a quotation

Cayman Pharma S.r.o is a supplier offers 7 products (APIs, Excipients or Intermediates).

Find a price of Epoprostenol Sodium bulk with DMF, JDMF offered by Cayman Pharma S.r.o

Find a price of Latanoprost bulk with DMF, JDMF offered by Cayman Pharma S.r.o

Find a price of Travoprost bulk with DMF, JDMF offered by Cayman Pharma S.r.o

Find a price of Bimatoprost bulk with DMF offered by Cayman Pharma S.r.o

Find a price of Latanoprostene Bunod bulk with DMF offered by Cayman Pharma S.r.o

Find a price of Tafluprost bulk with DMF offered by Cayman Pharma S.r.o

Find a price of Cloprostenol Sodium bulk offered by Cayman Pharma S.r.o